This increase in anti-tumor CD8 T cell to CD4, CD25 T cell ratio led to a significant reduction in tumor size when MSU42011 was combined with both anti-PD1 or anti-PDL1 antibodies in the A/J lung cancer model when compared with MSU42011 or anti-PD(L)1 antibodies alone (Figure 7 and Table 2). The gene discussed is CD4; the disease is lung carcinoma.